Evommune EVMN
NYSE EVMN
$6.88 -0.31 (-4.31%)
At close: Oct 2, 2026 · 4:00 PM EDT

Evommune (EVMN) Return on Sales [ROS] (2025 - 2026)

Updated

Evommune (EVMN) posted Return on Sales [ROS] of -1018.93% for Q2 2026, down 119.01 percentage points from the prior quarter.

Analysis

Evommune (EVMN) Return on Sales [ROS] (2025 - 2026) Analysis & Trends

For FY2025, Evommune's Return on Sales [ROS] came in at -623.62%, up 376.56 percentage points from FY2024.

  • In prior years, Evommune's Return on Sales [ROS] was -1000.19% in FY2024.
  • According to Business Quant data, Return on Sales [ROS] for the three prior quarters was -899.92% (Q1 2026), -623.62% (Q4 2025) and -133.28% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,082.65 Bn 1,051.23 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 623.68 Bn 542.21 Bn 17.26 Bn 28.21%
3 AbbVie 459.43 Bn 432.59 Bn 12.70 Bn 37.86%
4 Merck 354.80 Bn 309.23 Bn 12.21 Bn -3.52%
5 Novartis Ag 269.16 Bn 225.03 Bn 11.24 Bn 32.97%
6 Astrazeneca 244.40 Bn 217.97 Bn 12.86 Bn 20.57%
7 Amgen 220.17 Bn 175.57 Bn 7.24 Bn 34.95%
8 Gilead Sciences 183.05 Bn 157.16 Bn 6.22 Bn -133.21%
9 Pfizer 160.27 Bn 107.22 Bn 10.94 Bn 28.37%
10 Evommune 260.87 Mn -376.65 Mn - -1,018.93%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -1,018.93%
Mar 31, 2026 -899.92%
Dec 31, 2025 -623.62%
Sep 30, 2025 -133.28%
Mar 31, 2025 -501.07%
API Access

Evommune Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=EVMN&period=max&api_key=YOUR_API_KEY